Denosumab Biosimilar, Anti-human RANKL Antibody | Catalog C004P

Denosumab Biosimilar, Human RANKL Monoclonal Antibody. Denosumab biosimilar CHO stable cell line is available for licensing to manufacture the denosumab biosimilar protein. The research grade denosumab biosimilar protein is for research use only (RUO). Recombinant human IgG2 isotype controls are available.

Product Specifications

Catalog No.	C004P
Product Name	Denosumab Biosimilar, Human RANKL Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-RANKL Human Monoclonal Antibody
Summary	Recombinant Humanized IgG2 Monoclonal Antibody.
Source/Host	Produced in the denosumab biosimilar CHO stable cell line.
Specificity	Specifically binds to the human RANKL (RANK ligand) protein.

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.
Formulation	0.2 µM filtered solution, pH 5.2, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.